Latest news

PCI Biotech: US patent granted for the vaccine technology (fimaVACC) in combination with cytokines

Posted on Jan 21, 2020

Oslo (Norway), 21 January 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with cytokines. Cytokines are small proteins that are involved in cell signaling, and that are very […]

PCI Biotech to present Phase I fimaVACC results at ESMO Immuno-Oncology 2019

Posted on Dec 12, 2019

Oslo, Norway, December 12, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present results from the successful fimaVacc Phase I proof of concept study in healthy volunteers at the ESMO Immuno-Oncology Congress 2019 being held December 11-14, 2019 at Palexpo in Geneva, Switzerland. […]

PCI Biotech: Third quarter 2019 results

Posted on Nov 27, 2019

Oslo (Norway), 27 November 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its third quarter 2019 result. Please find enclosed the report and presentation. Highlights fimaChem *Start-up activities for the RELEASE study are progressing well after the study commenced with enrolment of the first patient in May 2019 *23 out […]